Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

738.00 -6.50 (-0.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
42 43 Next >
Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed
Read the latest report on Sunshine Biopharma here. 
Via Benzinga
Can These 2 Stocks Crush the Market Again in 2023?
Both are riding the wave of major clinical wins 
Via The Motley Fool
Regeneron's Evkeeza Under FDA Priority Review For Younger Kids With Inherited Form Of High Cholesterol
Via Benzinga
UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent
Via Benzinga
2 Market-Beating Stocks That Can Continue Rising in 2023
It's not too late to get in on the potential 2023 growth for these two stocks. 
Via The Motley Fool
Market Currents: Why Pick Stocks?
Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and... 
Via Talk Markets
CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron
Via Benzinga
Regeneron Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Regeneron Pharmaceuticals Tops Quarterly Expectations Despite Covid Shortfall
Excluding the year-earlier impact of the Covid drug, third-quarter sales grew 11%. 
Via Investor's Business Daily
Stock Market Investing Action Plan: What Part Of November Don't You Understand?
A turnabout month left the market sitting on some nice gains. The next week's data might determine whether those gains hold. 
Via Investor's Business Daily
Dexcom Leads 5 Stocks Near Buy Points
They combine strong technicals and generally sound fundamentals. 
Via Investor's Business Daily
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough." 
Via Benzinga
CytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat Cancer
CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company, which is focused on developing innovative treatments for a wide-range 
Via Spotlight Growth
Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?
CytomX Therapeutics (CTMX) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (REGN). 
Via InvestorPlace
Daily Stock Analysis: Sanofi - November 2022 Snapshot
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company's decided in late 2019 to pull back from the cardio-metabolic... 
Via Talk Markets
2 Top Biotech Stocks to Buy in November
Both of these companies have potential catalysts on the way. 
Via The Motley Fool
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen. 
Via Investor's Business Daily
$100 Invested In This Stock 15 Years Ago Would Be Worth $4,000 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 21.17% on an annualized basis producing an average annual return of 27.88%. Currently, Regeneron... 
Via Benzinga
7 Cash-Rich Stocks to Buy for Peace of Mind
It pays to hold cash-rich stocks that can weather any storm because of their financial strength. Investors may want to watch these seven. 
Via InvestorPlace
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review
A mixed jobs report and heavy earnings swung stocks. 
Via Investor's Business Daily
Regeneron Pharmaceuticals: Q3 Earnings Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange... 
Via Benzinga
Here's How Much $1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 21.24% on an annualized basis producing an average annual return of 27.82%. Currently, Regeneron... 
Via Benzinga
Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a ‘Blue Wave’
If you see a blue wave coming get out of the oilpatch, crypto, and pharmaceuticals that are subject to price regulation. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
Upgrades 
Via Benzinga
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
Biosimilars are bringing down prescription drug costs without sacrificing quality. 
Via The Motley Fool
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.